Tetherin antagonism by SARS‐CoV‐2 ORF3a and spike protein enhances virus release
The EMBO Reports · 06.12.2023 · 24 (12)
DOI: 10.15252/embr.202357224 ↗Kurz gefasst
Fachartikel in der Zeitschrift The EMBO Reports, online erschienen am 11.10.2023. Verfasst von Hazel Stewart und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Bone Marrow Stromal Antigen 2, COVID-19, SARS-CoV-2, Spike Glycoprotein, Coronavirus. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust, EC | European Research Council, Royal Society.
Abstract (Originalsprache)
The antiviral restriction factor, tetherin, blocks the release of several different families of enveloped viruses, including the Coronaviridae. Tetherin is an interferon‐induced protein that forms parallel homodimers between the host cell and viral particles, linking viruses to the surface of infected cells and inhibiting their release. We demonstrate that SARS‐CoV‐2 infection causes tetherin downregulation and that tetherin depletion from cells enhances SARS‐CoV‐2 viral titres. We investigate the potential viral proteins involved in abrogating tetherin function and find that SARS‐CoV‐2 ORF3a reduces tetherin localisation within biosynthetic organelles where Coronaviruses bud, and increases tetherin localisation to late endocytic organelles via reduced retrograde recycling. We also find that expression of Spike protein causes a reduction in cellular tetherin levels. Our results confirm that tetherin acts as a host restriction factor for SARS‐CoV‐2 and highlight the multiple distinct mechanisms by which SARS‐CoV‐2 subverts tetherin function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Cambridge, Cambridge, UK.
- Laboratory of Immune Systems Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
- Department of Biomedical Science, University of Sheffield, Firth Court, Sheffield, UK.
- Department of Veterinary Medicine, University of Cambridge, Cambridge, UK.
- Department of Infectious Disease, Imperial College London, London, UK.
- Royal Brompton Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK.
ORCID-Profile: Hazel Stewart, Roberta Palmulli, Kristoffer H Johansen, Naomi McGovern, Hannah K Jackson, Jin S Lee, Jonathan C Brown, Klaus Okkenhaug, Andrew A Peden, James R Edgar
Förderung
- Wellcome Trust
- EC | European Research Council
- Royal Society
- UKRI | Biotechnology and Biological Sciences Research Council
- UKRI | Innovate UK
Zitieren
APA
Stewart, H., Palmulli, R., Johansen, K. H., McGovern, N., Shehata, O. M., Carnell, G. W., Jackson, H. K., Lee, J. S., Brown, J. C., Burgoyne, T., Heeney, J. L., Okkenhaug, K., Firth, A. E., Peden, A. A., & Edgar, J. R. (2023). Tetherin antagonism by SARS‐CoV‐2 ORF3a and spike protein enhances virus release. The EMBO Reports, 24(12). https://doi.org/10.15252/embr.202357224
Vancouver
Stewart H, Palmulli R, Johansen KH, McGovern N, Shehata OM, Carnell GW, et al. Tetherin antagonism by SARS‐CoV‐2 ORF3a and spike protein enhances virus release. The EMBO Reports. 2023;24(12). doi:10.15252/embr.202357224
BibTeX
@article{Stewart2023,
author = {Stewart, Hazel and Palmulli, Roberta and Johansen, Kristoffer H and McGovern, Naomi and Shehata, Ola M and Carnell, George W and Jackson, Hannah K and Lee, Jin S and Brown, Jonathan C and Burgoyne, Thomas and Heeney, Jonathan L and Okkenhaug, Klaus and Firth, Andrew E and Peden, Andrew A and Edgar, James R},
title = {Tetherin antagonism by SARS‐CoV‐2 ORF3a and spike protein enhances virus release},
journal = {The EMBO Reports},
year = {2023},
volume = {24},
number = {12},
doi = {10.15252/embr.202357224}
}
EUVIMED